Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Erlotinib
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Erlotinib 100mg tablets
0801050AEAAAAAA
|
Erlotinib | Erlotinib | Malignant Disease and Immunosuppression | No data available |
|
Erlotinib 150mg tablets
0801050AEAAABAB
|
Erlotinib | Erlotinib | Malignant Disease and Immunosuppression | No data available |
|
Erlotinib 25mg tablets
0801050AEAAACAC
|
Erlotinib | Erlotinib | Malignant Disease and Immunosuppression | No data available |
|
Tarceva 100mg tablets
0801050AEBBAAAA
|
Tarceva | Erlotinib | Malignant Disease and Immunosuppression | No data available |
|
Tarceva 150mg tablets
0801050AEBBABAB
|
Tarceva | Erlotinib | Malignant Disease and Immunosuppression | No data available |
|
Tarceva 25mg tablets
0801050AEBBACAC
|
Tarceva | Erlotinib | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.